(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of 5.09% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Becton Dickinson & Co's revenue in 2024 is $19,492,000,000.On average, 8 Wall Street analysts forecast BDX's revenue for 2024 to be $5,862,188,570,679, with the lowest BDX revenue forecast at $5,832,684,719,138, and the highest BDX revenue forecast at $5,874,087,298,006. On average, 8 Wall Street analysts forecast BDX's revenue for 2025 to be $6,205,728,570,599, with the lowest BDX revenue forecast at $6,181,063,253,640, and the highest BDX revenue forecast at $6,252,422,104,944.
In 2026, BDX is forecast to generate $6,529,310,048,724 in revenue, with the lowest revenue forecast at $6,508,412,594,675 and the highest revenue forecast at $6,566,880,050,582.